ArticleMolecular vision2009
Alteration of ocular surface mucins in MUC5AC-DTA transgenic mice.
Article in Molecular vision, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- The role of epithelial membrane-associated mucin 4 in ocular surface health and corneal wound healing.Frontiers in medicine · 2025Article
- Role for Mucin-5AC in Upper and Lower Airway Pathogenesis in Mice.Toxicologic pathology · 2021Article
- Mucus models to evaluate the diffusion of drugs and particles.Advanced drug delivery reviews · 2018Review
- Ocular surface mucins and local inflammation--studies in genetically modified mouse lines.BMC ophthalmology · 2015Review
- A secretory cell type develops alongside multiciliated cells, ionocytes and goblet cells, and provides a protective, anti-infective function in the frog embryonic mucociliary epidermis.Development (Cambridge, England) · 2014Article
- Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.Experimental eye research · 2013Article
- Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the compensation of secretory mucins with membranous mucins in mice with goblet cell deficiency.
methodsA transgenic mouse model in which conjunctival goblet cells were targeted was generated, and the expression of mucins was evaluated through the toxicity of diphtheria toxin A driven by a human mucin, MUC5AC, promoter. Immunohistochemical staining, in situ hybridization, electronic microscopy, and quantitative reverse transcription polymerase chain reaction (RT-PCR) were used to characterize their phenotypes.
resultsThe external appearance of the ocular surface was normal, and no corneal pathology was found. The quantity of MUC5AC and the number of conjunctival goblet cells decreased in this mouse as expected. However, the membranous mucin, MUC4, compensates the decrease of MUC5AC in terms of the results of immunohistochemical staining, in situ hybridization, electronic microscopy, and quantitative RT-PCR.
conclusionsThe membranous mucin, MUC4, can compensate for the deficiency of the secretory mucin, MUC5AC, in goblet cell deficient mice. This compensation may explain why the symptoms of mucus threads can be found in some goblet deficiency diseases, and it may provide an alternative defensive mechanism in goblet cell deficiency.
Indexed as
Identifiers
19158956PMC2628312W1567006352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.